Radiographic assessment and intratumoral pharmacodynamics
inflammation, tumor, HPV16 E6
INFLAMMATION, DISEASE, INFILTRATING, TUMOR
Of the 18 treated patients, 17 were evaluated for response. Four patients had stable disease as their best response, and one patient (#17) had a best overall response of unconfirmed partial response (Supplementary Fig. Seventeen paired biopsy samples were examined. The tumor microenvironment (TME) was histologically graded for inflammation phenotype, and changes were assessed in CD8+ cell density, FoxP3+ cell density, CD8+/GZMB+ cell density, HPV16 E6 and E7 transcript levels, PD-L1 and MHC-I presence on tumor cells (Figs. CD8+ tumor infiltrating lymphocytes, as determined by histology analyses using tumor biopsy samples collected during subject screening (within 28 days of first treatment) and at day 28 (cycle 2 day 8) following the first infusion of SQZ-PBMC-HPV. Cohort abbreviations as in Fig. Imaging results and pharmacodynamic parameters for patient 17. For patient 17 in the High Dose - Double Prime cohort, the influx of CD8+ cells observed in the biopsy coincided with a change of the immunophenotype from desert to inflamed [